Clinical trials: Covid19 Vaccine
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above
This is a non-randomized, open-label, externally controlled study to evaluate the safety and immnunogenicity of the Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above with no vaccination…
- Trial name
- COVID-19 (NCT05365724)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19 Pneumonia
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05057923
- Testing
- Bacillus subtilis
- Where
- Hong Kong
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
Covid19
Study of GRAd-COV2 for the Prevention of COVID-19 in Adults
Multicenter Study assessing the safety, efficacy, and immunogenicity of the candidate vaccine GRAd-COV2, compared to placebo, for the prevention of COVID-19.
- Trial name
- COVITAR (NCT04791423)
- Testing
- GRAd-COV2
- Where
- 26 sites in Italy
- Volunteers
- 10,300 people, healthy volunteers welcome
- Sponsor
- ReiThera Srl
COVID-19
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
The objective is to evaluate the safety and immunogenicity of AZD1222 given in combination with (either before or after) rAd26-S, for the prevention of COVID 19 in adults ≥ 18 years of age.
- Trial name
- NCT04684446
- Testing
- AZD1222, rAd26-S
- Where
- 4 sites in Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
COVID-19
A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children
The purpose of this clinical trial is to learn about the safety and immune responses of the study vaccine (called a bivalent BNT162b2 Omicron containing vaccine) in healthy infants and children.
- Trial name
- NCT05630352
- Testing
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
- Volunteers
- healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine.
- Trial name
- NCT06680375
- Testing
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA
- Where
- 9 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19
This is the first study of COVI-VAC in humans. The purpose of the study is to evaluate the safety and immune response of COVI-VAC (a live attenuated vaccine to prevent COVID-19) in healthy adults aged 18 to 30 years.
- Trial name
- NCT04619628
- Testing
- COVI-VAC
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Covid19
Views on COVID-19 and Vaccination
The goal of this study is to develop evidence-based messages that effectively mitigate concerns of people at risk for not being vaccinated against COVID-19, with the ultimate goal of maximizing vaccine uptake in vulnerable…
- Trial name
- NCT04706403
- Testing
- Communication from a physician about the COVID-19 Vaccine
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- University of Massachusetts, Worcester
SARS-CoV-2
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants Aged 18 years and over in China
- Trial name
- NCT05547256
- Testing
- COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose, COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
SARS-CoV-2 Infection
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 3, 4, 5, or 6 months since finished two doses schedule…
- Trial name
- NCT05163652
- Testing
- SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
- Where
- China
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
COVID-19
Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly
This is an open phase Ⅲ clinical trial of COVID-19 vaccine (Vero cell), inactivated manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate Immunogenicity and safety of a third dose at…
- Trial name
- NCT05398926
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Covid19
COVID-19 Vaccine Text Outreach
This project aims to evaluate different approaches to increase COVID-19 vaccine uptake among at-risk patients at Penn Medicine in an equitable and systematic manner through a centralized outreach program.
- Trial name
- NCT04834726
- Testing
- Opt-In (Call-Back), Opt-in (In-Bound), Standard Message
- Where
- United States
- Volunteers
- 19,554 people
- Sponsor
- University of Pennsylvania
SARS-CoV Infection
Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19
The study is designed to evaluate the safety, reactogenicity, and immunogenicity of three groups of healthy volunteers who receive either intranasal single dose (vaccine on Day 0 and placebo on Day 28) or two-dose (vaccine on Day…
- Trial name
- NCT04751682
- Testing
- BBV154 Vaccine
- Where
- 4 sites in India
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Infectious Disease, COVID-19
Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals
Phase 1b, randomized, open-label, study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 only, RVM-V002 only, or RVM V001 + RVM V002 (Co administered as Separate Injections) in healthy adults.
- Trial name
- NCT05788185
- Testing
- RVM-V001 30 µg, RVM-V002 30 µg, RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- RVAC Medicines (US), Inc.
COVID-19
Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine
Observer-blind, randomized, active-controlled prospective intervention study
- Trial name
- NCT05433285
- Testing
- COVID-19 Protein Subunit Recombinant Vaccine, Active Comparator
- Where
- 4 sites in Indonesia
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
COVID-19 Vaccine
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
This is an open-label and non-randomized study to demonstrate the immunogenicity and safety profile in adults that received the Ad5-nCoV vaccine at least 21 days but no later than 90 days after the first dose of Sputnik V.
- Trial name
- FH-63 (NCT05293223)
- Testing
- Ad5-nCov
- Where
- 3 sites in Argentina
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Fundación Huésped
Healthy Volunteer
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
Background: Vaccines help prevent disease by causing the body to have an immune response. Many parts of this response happen in the blood. This response happens over days and weeks after getting the vaccine.
- Trial name
- NCT04025580
- Testing
- Flucelvax, Fluvirin, Fluzone High Dose
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination…
- Trial name
- NCT05193279
- Testing
- Candidate vaccine, SCB-2019
- Where
- 2 sites in Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Immunogenicity, Vaccine
Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece
Real-world evidence confirming the effectiveness and safety of the new COVID-19 vaccines among the elderly is currently lacking.
- Trial name
- GREVAXIMO (NCT04756817)
- Where
- Greece
- Volunteers
- 297 people
- Sponsor
- G.Gennimatas General Hospital
Covid19
COVID-19 Vaccination of Immunodeficient Persons (COVAXID)
The study is designed as an open, non-randomized, phase IV cohort study in which the mRNA vaccine Comirnaty will be given in two doses.
- Trial name
- COVAXID (NCT04780659)
- Testing
- Comirnaty (COVID-19, mRNA vaccine)
- Where
- Sweden
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.